Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. (Q50283544)

From Wikidata

Jump to navigation Jump to search

scientific article published on 6 May 2014

Language	Label	Description	Also known as
English	Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C.	scientific article published on 6 May 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

Kazuaki Chayama

22

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

2

object named as

Michio Imamura

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

18

object named as

Hiroshi Aikata

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Tomokazu Kawaoka

15

object named as

Tomokazu Kawaoka

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

16

object named as

Masataka Tsuge

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Yoshiiku Kawakami

3

object named as

Yoshiiku Kawakami

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Akira Hiramatsu

17

object named as

Akira Hiramatsu

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Shoichi Takahashi

19

object named as

Shoichi Takahashi

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

21

object named as

Hidenori Ochi

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

20

object named as

C Nelson Hayes

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Takashi Nakahara

9

object named as

Takashi Nakahara

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

5

object named as

Hatsue Fujino

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

8

object named as

Atsushi Ono

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

4

object named as

Hiromi Kan

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Tomoki Kobayashi

7

object named as

Tomoki Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Takayuki Fukuhara

6

object named as

Takayuki Fukuhara

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

1

object named as

Yuko Nagaoki

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

author name string

Noriaki Naeshiro

10

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Ayako Urabe

11

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Satoe Yokoyama

12

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Daisuke Miyaki

13

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Eisuke Murakami

14

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Hiroshima Liver Study Group

23

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

publication date

6 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Hepatology Research

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

44

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

14

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

E447-54

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

A high-throughput SNP typing system for genome-wide association studies

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12336

21 January 2018

Identifiers

10.1111/HEPR.12336

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 March 2018

http://europepmc.org/abstract/MED/24690180

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50283544&oldid=1891009477"